Insider Transactions Reported | Ionis Pharmaceuticals(IONS)saw insider trading activity on 8/26/2025

Ionis Pharmaceuticals(IONS) saw insider trading activity on 8/26/2025, there was 1 insider trade during the day.

【History Insider Transaction】

Declare date	Position	Name	Buy/Sell	Quantity	Price per share/USD	Total Amount/USD
8/26/2025	--	Diaz Allene M.	Sell	1427	42.53	60.69k
8/20/2025	EVP, Chief Scientific Officer	BENNETT C FRANK	Sell	10000	43.98	439.78k
8/20/2025	EVP, Chief Scientific Officer	BENNETT C FRANK	Buy	10000	32.60	326.0k
8/6/2025	EVP, Chief Development Officer	Geary Richard S	Sell	10000	42.86	428.59k
8/5/2025	EVP, Chf Clinical Develop Ofcr	Schneider Eugene	Sell	9549	42.80	408.7k
8/1/2025	Chief Executive Officer	Monia Brett P	Buy	2432	32.60	79.28k
8/1/2025	Chief Executive Officer	Monia Brett P	Sell	2432	45.00	109.44k
7/15/2025	Chief Executive Officer	Monia Brett P	Sell	1160	41.74	48.42k
5/2/2025	--	Hayden Michael R	Buy	15000	31.86	477.9k
4/17/2025	EVP, Chief Business Officer	Baroldi Joseph	Sell	3928	28.40	111.56k

[Company Profile]
Ionis Pharmaceuticals, Inc. is the leading company in antisense drug discovery and development, exploiting a novel drug discovery platform the company created to generate a broad pipeline of first-in-class drugs. Antisense technology provides a direct route from genomics to drugs. With the company's highly efficient and prolific drug discovery platform the company can expand its pipeline and its partners' pipelines with antisense drugs that address significant medical needs. The company's strategy is to do what the company does best—to discover unique antisense drugs and develop these drugs to key clinical value inflection points. The company discovers and conducts early development of new drugs and, at the key clinical value inflection points, outlicense its drugs to partners. The company maximizes the value of the drugs the company discovers by putting them in the hands of leading pharmaceutical companies with late-stage development, commercialization and marketing expertise, such as Biogen Idec, Bristol-Myers Squibb, Genzyme, a Sanofi company, GlaxoSmithKline, or GSK, and Eli Lilly and Company. The company's flagship product, KYNAMRO, is moving closer to the market for patients with severe forms of familial hypercholesterolemia, or FH, at high cardiovascular risk, who cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies. The company was incorporated in California in 1989.